NCT05190770 - A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

August 27, 2024

Study Completion Date

August 27, 2024

Conditions

Breast CancerBreast Cancer StageBreast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage IIIBreast Cancer Stage IV

Interventions

DRUG

Triamcinolone Acetonide

Triamcinolone acetonide is a derivative of prednisolone with high glucocorticoid activity and low mineralocorticoid activity. It is applied topically.

DRUG

Oleogel-S10

Oleogel-S10 consists of birch bark extract (TE): 10 mg/100 mg; Sunflower oil, refined: 90 mg/100 mg. It is applied topically.

Trial Locations (4)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

07920

Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (All protocol activities), Middletown

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER